Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
2.310
+0.300 (14.93%)
At close: Nov 22, 2024, 4:00 PM
2.340
+0.030 (1.30%)
After-hours: Nov 22, 2024, 6:39 PM EST
Inhibikase Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 0 | 0.26 | 0.12 | 3.1 | 0.7 | 1.12 | |
| Revenue Growth (YoY) | -100.00% | 111.03% | -96.02% | 343.92% | -37.79% | -72.22% | |
| Cost of Revenue | 13.62 | 13.62 | 12.03 | 11.36 | 0.89 | 2.55 | |
| Gross Profit | -13.62 | -13.36 | -11.91 | -8.26 | -0.2 | -1.43 | |
| Selling, General & Admin | 7.04 | 6.73 | 6.22 | 6.51 | 2.62 | 4.27 | |
| Operating Expenses | 6.45 | 6.73 | 6.22 | 6.51 | 2.62 | 4.27 | |
| Operating Income | -20.06 | -20.09 | -18.13 | -14.77 | -2.82 | -5.7 | |
| Interest Expense | - | - | - | -0.02 | -0.03 | -0.02 | |
| Interest & Investment Income | 0.5 | 1.06 | 0.07 | - | - | - | |
| Pretax Income | -19.57 | -19.03 | -18.05 | -14.79 | -2.85 | -5.72 | |
| Net Income | -19.57 | -19.03 | -18.05 | -14.79 | -2.85 | -5.72 | |
| Net Income to Common | -19.57 | -19.03 | -18.05 | -14.79 | -2.85 | -5.72 | |
| Shares Outstanding (Basic) | 7 | 5 | 4 | 3 | 1 | 1 | |
| Shares Outstanding (Diluted) | 7 | 5 | 4 | 3 | 1 | 1 | |
| Shares Change (YoY) | 18.14% | 26.28% | 39.15% | 121.72% | 0.39% | 2.08% | |
| EPS (Basic) | -2.99 | -3.57 | -4.28 | -4.87 | -2.08 | -4.20 | |
| EPS (Diluted) | -2.99 | -3.57 | -4.28 | -4.87 | -2.08 | -4.20 | |
| Free Cash Flow | -17.24 | -18.1 | -17.59 | -14.3 | -1.13 | -0.34 | |
| Free Cash Flow Per Share | -2.64 | -3.39 | -4.17 | -4.71 | -0.83 | -0.25 | |
| Gross Margin | - | - | - | -266.35% | -27.97% | -127.36% | |
| Operating Margin | -2006393400.00% | -7711.98% | -14686.17% | -476.23% | -403.52% | -507.52% | |
| Profit Margin | -1956524900.00% | -7304.73% | -14625.85% | -476.88% | -407.73% | -509.73% | |
| Free Cash Flow Margin | -1724492300.00% | -6947.87% | -14253.37% | -461.11% | -161.69% | -30.13% | |
| EBITDA | -20.04 | -19.91 | -18.12 | - | - | - | |
| D&A For EBITDA | 0.03 | 0.18 | 0.01 | - | - | - | |
| EBIT | -20.06 | -20.09 | -18.13 | -14.77 | -2.82 | -5.7 | |
| Revenue as Reported | 0 | 0.26 | 0.12 | 3.1 | 0.7 | 1.12 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.